Next generation BRAF inhibitor cancer drug shows promise in early patient trial

(European Organisation for Research and Treatment of Cancer) A new drug designed to work on cancers with an altered BRAF gene has shown promise in an early patient trial presented at the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, which is taking place online.